Customize your JAMA Network experience by selecting one or more topics from the list below.
• To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550±$1,740 for cefotaxime and $3,160±$1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980±$1,800 for cefotaxime and $4,170±$1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.
(Arch Intern Med 1986;146:1153-1157)
Moore RD, Smith CR, Holloway JJ, Lietman PS. Cefotaxime vs Nafcillin and Tobramycin for the Treatment of Serious Infection: Comparative Cost-effectiveness. Arch Intern Med. 1986;146(6):1153–1157. doi:10.1001/archinte.1986.00360180159024
Create a personal account or sign in to: